Summary of Lucid Diagnostics Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Recognized revenue for Q2 2026 was $1.5 million, a 17% increase from the prior quarter, with 2,770 EsoGuard tests performed.

Test Volume: Volume remained stable within the target range of 2,500 to 3,000 tests.

Cash Position: Cash at the end of Q2 was $33.4 million, flat compared to year-end.

Operating Expenses: Total operating expenses increased by about 5% quarter-over-quarter, reflecting higher commercial activities.

Net Loss: Non-GAAP net loss per share improved to $0.06, better than previous quarters.

Burn Rate: Average burn rate for the last four quarters was $11.6 million, with Q2 slightly lower at $11.3 million.

2Strategic Updates and Business Highlights

Medicare Coverage: Awaiting publication of a draft Local Coverage Determination (LCD) from Medicare, with confidence in a positive outcome despite a backlog at CMS.

Commercial Coverage: Secured first laboratory benefit manager (LBM) policy from Concert, which has been adopted by three client health plans, validating EsoGuard's clinical evidence.

VA Engagement: Progressing well with Veterans Affairs (VA) centers, focusing on securing contracts for the new federal fiscal year starting October 1.

Cost-Effectiveness Model: Development of a sophisticated cost-effectiveness model for EsoGuard, expected to demonstrate long-term clinical and economic benefits.

3Forward Guidance and Outlook

Test Volume Targets: Continuing to target 2,500 to 3,000 tests per quarter, with expectations for increased volume as Medicare coverage and VA contracts materialize.

Revenue Growth: Anticipated growth from secured commercial coverage and ongoing VA engagements, with a focus on increasing visibility and strategic partnerships.

4Bad News, Challenges, or Points of Concern

Medicare Delays: Ongoing delays in Medicare LCD publication present uncertainty and could impact revenue recognition for a significant portion of the patient population (40-50%).

Denial Rates: Approximately one-third of adjudicated claims resulted in denials, with common reasons including "medically not necessary" and "experimental or investigational."

Cash Burn Management: While the burn rate is stable, any increase in operating expenses could strain cash reserves if not matched by revenue growth.

5Notable Q&A Insights

VA Contribution: The VA has not yet contributed significantly to test volume, but contracts are being secured, which may lead to future volume increases.

Commercial Strategy: The company is shifting focus from firefighter health events to traditional primary care and GI engagements to drive test volume.

Concierge Medicine: The company has deprioritized concierge medicine due to high resource demands and limited returns.

Cost-Effectiveness Metrics: While specific metrics are not disclosed yet, initial results from the cost-effectiveness model are promising and will be submitted for publication.

Hiring Strategy: The company is focused on recruiting sales personnel with diverse backgrounds, emphasizing training to enhance effectiveness in physician engagement. Overall, Lucid Diagnostics is making steady progress in its commercialization efforts and is optimistic about future revenue growth, although it faces challenges related to Medicare coverage delays and claim denials.